These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37368513)

  • 61. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study.
    Brouha SS; Nguyen P; Bettencourt R; Sirlin CB; Loomba R
    Eur Radiol; 2018 Apr; 28(4):1345-1355. PubMed ID: 29058029
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of Magnetic Resonance-Based Elastography and Ultrasound Shear Wave Elastography in Patients With Suspicion of Nonalcoholic Fatty Liver Disease.
    Tahmasebi A; Wessner CE; Guglielmo FF; Wang S; Vu T; Liu JB; Civan J; Lyshchik A; Forsberg F; Li H; Qu E; Eisenbrey JR
    Ultrasound Q; 2023 Jun; 39(2):100-108. PubMed ID: 36943721
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.
    Nakajima A; Eguchi Y; Yoneda M; Imajo K; Tamaki N; Suganami H; Nojima T; Tanigawa R; Iizuka M; Iida Y; Loomba R
    Aliment Pharmacol Ther; 2021 Nov; 54(10):1263-1277. PubMed ID: 34528723
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD-NASH Cohort.
    Troelstra MA; Witjes JJ; van Dijk AM; Mak AL; Gurney-Champion O; Runge JH; Zwirs D; Stols-Gonçalves D; Zwinderman AH; Ten Wolde M; Monajemi H; Ramsoekh S; Sinkus R; van Delden OM; Beuers UH; Verheij J; Nieuwdorp M; Nederveen AJ; Holleboom AG
    J Magn Reson Imaging; 2021 Dec; 54(6):1937-1949. PubMed ID: 33991378
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
    Sangha K; Chang ST; Cheung R; Deshpande VS
    Hepatology; 2023 May; 77(5):1702-1711. PubMed ID: 37018145
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.
    Caussy C; Reeder SB; Sirlin CB; Loomba R
    Hepatology; 2018 Aug; 68(2):763-772. PubMed ID: 29356032
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
    Alkhouri N; Herring R; Kabler H; Kayali Z; Hassanein T; Kohli A; Huss RS; Zhu Y; Billin AN; Damgaard LH; Buchholtz K; Kjær MS; Balendran C; Myers RP; Loomba R; Noureddin M
    J Hepatol; 2022 Sep; 77(3):607-618. PubMed ID: 35439567
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Harmonized Multisite MRI-Based Quantification of Human Liver Fat and Stiffness: A Pilot Study.
    Carmichael OT; Singh M; Bashir A; Russell AM; Bolding M; Redden DT; Storrs J; Willoughby WR; Howard-Claudio C; Hsia DS; Kimberly RP; Gray ME; Ravussin E; Denney TS
    J Magn Reson Imaging; 2024 Mar; 59(3):1070-1073. PubMed ID: 37246446
    [TBL] [Abstract][Full Text] [Related]  

  • 69. MR Elastography: Practical Questions, From the
    Yin M; Ehman RL
    AJR Am J Roentgenol; 2024 Jan; 222(1):e2329437. PubMed ID: 37162036
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography.
    Yin Z; Murphy MC; Li J; Glaser KJ; Mauer AS; Mounajjed T; Therneau TM; Liu H; Malhi H; Manduca A; Ehman RL; Yin M
    Eur Radiol; 2019 Nov; 29(11):5823-5831. PubMed ID: 30887196
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH.
    Li J; Lu X; Zhu Z; Kalutkiewicz KJ; Mounajjed T; Therneau TM; Venkatesh SK; Sui Y; Glaser KJ; Hoodeshenas S; Manduca A; Shah VH; Ehman RL; Allen AM; Yin M
    Hepatology; 2023 Oct; 78(4):1200-1208. PubMed ID: 37080558
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association between Liver MRI Proton Density Fat Fraction and Liver Disease Risk.
    Xia T; Du M; Li H; Wang Y; Zha J; Wu T; Ju S
    Radiology; 2023 Oct; 309(1):e231007. PubMed ID: 37874242
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease.
    Lee YS; Yoo YJ; Jung YK; Kim JH; Seo YS; Yim HJ; Kim IH; Lee SY; Kim BH; Kim JW; Lee CH; Yeon JE; Kwon SY; Um SH; Byun KS
    Clin Transl Gastroenterol; 2020 Apr; 11(4):e00157. PubMed ID: 32251018
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diagnostic Performance of Vibration-Controlled Transient Elastography in Liver Transplant Recipients.
    Siddiqui MS; Idowu MO; Stromberg K; Sima A; Lee E; Patel S; Ghaus S; Driscoll C; Sterling RK; John B; Bhati CS
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):367-374. PubMed ID: 32272251
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Quantitative Ultrasound Biomarkers to Assess Nonalcoholic Fatty Liver Disease.
    Gao J; Zapata I; Chen J; Erpelding TN; Adamson C; Park D
    J Ultrasound Med; 2023 Aug; 42(8):1675-1688. PubMed ID: 36744595
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease.
    Lee HA; Kim SS; Choi JY; Seo YS; Park BJ; Sim KC; Kim SU
    Abdom Radiol (NY); 2022 Nov; 47(11):3733-3745. PubMed ID: 35962809
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease.
    Shima T; Sakai K; Oya H; Katayama T; Mitsumoto Y; Mizuno M; Kanbara Y; Okanoue T
    J Gastroenterol; 2020 Jan; 55(1):100-112. PubMed ID: 31538241
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled transient elastography.
    Tafur M; Cheung A; Menezes RJ; Feld J; Janssen H; Hirschfield GM; Jhaveri KS
    Eur Radiol; 2020 Jul; 30(7):3735-3747. PubMed ID: 32130494
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of hepatic steatosis on native T1 mapping of 3T magnetic resonance imaging in the assessment of T1 values for patients with non-alcoholic fatty liver disease.
    Ahn JH; Yu JS; Park KS; Kang SH; Huh JH; Chang JS; Lee JH; Kim MY; Nickel MD; Kannengiesser S; Kim JY; Koh SB
    Magn Reson Imaging; 2021 Jul; 80():1-8. PubMed ID: 33798658
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis.
    Alkhouri N; Lazas D; Loomba R; Frias JP; Feng S; Tseng L; Balic K; Agollah GD; Kwan T; Iyer JS; Morrow L; Mansbach H; Margalit M; Harrison SA
    Aliment Pharmacol Ther; 2023 Nov; 58(10):1005-1015. PubMed ID: 37718721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.